The second type, the non-TRU-type is a lung adenocarcinoma with a mesenchymal-like, more malignant phenotype harboring concomitant BRG1 and BRM protein loss, which then accelerates the tumor to have poor differentiation with epithelial-mesenchymal transition (EMT) and eventually a poorer prognosis as compared to the single loss of BRG1. This evidence concerns the gene SMARCA4 and lung adenocarcinoma.